Deutsch English Français

Contact

EP2493917

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP2493917

EP2493917 - BREAST TUMOR MARKERS AND METHODS OF USE THEREOF [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 16.10.2020 Database last updated on 14.03.2026
Former	The patent has been granted Status updated on 08.11.2019
Former	Grant of patent is intended Status updated on 20.06.2019
Former	Examination is in progress Status updated on 02.06.2017
Most recent event Tooltip	08.07.2022	Lapse of the patent in a contracting state New state(s): MK	published on 10.08.2022 [2022/32]
Applicant(s)	For all designated states EXTERNAUTICS SOCIETA' A RESPONSABILITA' LIMITATA "SOCIETA' IN LIQUIDAZIONE" Via Fiorentina 1 53100 Siena / IT
	[N/P]
Former [2019/30]	For all designated states EXTERNAUTICS S.P.A. Via Fiorentina 1 53100 Siena / IT
Former [2019/29]	For all designated states Externautics S.p.A. Via Fiorentina 1 53100 Siena / IT
Former [2012/36]	For all designated states Externautics S.p.A. Via Fiorentina, 1 53100 Siena / IT
Inventor(s)	01 / GRIFANTINI, Renata c/o EXTERNAUTICS S.P.A Via Fiorentina 1 53100 Siena / IT
	02 / PILERI, Piero c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 53100 Siena / IT
	03 / CAMPAGNOLI, Susanna c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 53100 Siena / IT
	04 / GRANDI, Alberto c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 53100 Siena / IT
	05 / PARRI, Matteo c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 53100 Siena / IT
	06 / PIERLEONI, Andrea c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 53100 Siena / IT
	07 / NOGAROTTO, Renzo c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 53100 Siena / IT
	[2019/50]
Former [2012/36]	01 / GRIFANTINI, Renata c/o EXTERNAUTICS S.P..A Via Fiorentina 1 I-53100 Siena / IT
	02 / PILERI, Piero c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 I-53100 Siena / IT
	03 / CAMPAGNOLI, Susanna c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 I-53100 Siena / IT
	04 / GRANDI, Alberto c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 I-53100 Siena / IT
	05 / PARRI, Matteo c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 I-53100 Siena / IT
	06 / PIERLEONI, Andrea c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 I-53100 Siena / IT
	07 / NOGAROTTO, Renzo c/o EXTERNAUTICS S.P.A. Via Fiorentina 1 I-53100 Siena / IT
Representative(s)	Banfi, Paolo Bianchetti & Minoja with Trevisan & Cuonzo IPS Srl Via Plinio, 63 20129 Milano / IT
	[N/P]
Former [2019/50]	Banfi, Paolo Bianchetti Bracco Minoja S.r.l. Via Plinio, 63 20129 Milano / IT
Former [2012/36]	Banfi, Paolo Bianchetti Bracco Minoja S.r.l. Via Plinio, 63 20129 Milano / IT
Application number, filing date	10787709.4	26.10.2010
	[2019/50]
	WO2010EP66146
Priority number, date	EP20090174060	26.10.2009 Original published format: EP 09174060
	[2012/36]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2011051277
	Date:	05.05.2011
	Language:	EN
	[2011/18]
	Type:	A1 Application with search report
	No.:	EP2493917
	Date:	05.09.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 05.05.2011 takes the place of the publication of the European patent application.
	[2012/36]
	Type:	B1 Patent specification
	No.:	EP2493917
	Date:	11.12.2019
	Language:	EN
	[2019/50]
	Type:	B8 Corrected title page of specification
	No.:	EP2493917
	Date:	04.03.2020
	[2020/10]
Search report(s)	International search report - published on:	EP	05.05.2011
Classification	IPC:	C07K14/47, G01N33/50, G01N33/574	[2012/36]
	CPC:	G01N33/57515 (EP,US); C07K14/4748 (EP,US); C07K16/3015 (US); C07K16/44 (US); C12N15/1135 (US); C12Q1/6886 (US); (+) G01N33/5011 (EP,US); C12N2310/111 (US); C12N2310/14 (US); C12Q2600/158 (US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2012/36]
Extension states	BA	Not yet paid
	ME	Not yet paid
Title	German:	BRUSTTUMORMARKER UND DEREN VERWENDUNG	[2018/48]
	English:	BREAST TUMOR MARKERS AND METHODS OF USE THEREOF	[2012/36]
	French:	MARQUERS DE LA TUMEUR DU SEIN ET LEUR UTILISATION	[2018/48]
	Former [2012/36]	BRUSTKREBSMARKER UND VERFAHREN ZU IHRER VERWENDUNG
	Former [2012/36]	MARQUEURS DE TUMEURS DU SEIN ET LEURS MÉTHODES D'UTILISATION
Entry into regional phase	22.05.2012	National basic fee paid
	22.05.2012	Designation fee(s) paid
	22.05.2012	Examination fee paid
Examination procedure	22.05.2012	Examination requested [2012/36]
	21.03.2013	Amendment by applicant (claims and/or description)
	05.12.2013	Despatch of a communication from the examining division (Time limit: M06)
	03.06.2014	Reply to a communication from the examining division
	20.02.2015	Despatch of a communication from the examining division (Time limit: M06)
	29.09.2015	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
	04.12.2015	Reply to a communication from the examining division
	24.05.2017	Despatch of a communication from the examining division (Time limit: M06)
	29.11.2017	Reply to a communication from the examining division
	21.06.2019	Communication of intention to grant the patent
	30.10.2019	Fee for grant paid
	30.10.2019	Fee for publishing/printing paid
	30.10.2019	Receipt of the translation of the claim(s)
Divisional application(s)	EP17209384.1 / EP3345920
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 05.12.2013
Opposition(s)	14.09.2020	No opposition filed within time limit [2020/47]
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	04.12.2015	Request for further processing filed
	04.12.2015	Full payment received (date of receipt of payment) Request granted
	16.12.2015	Decision despatched
	21.03.2013	Request for further processing filed
	21.03.2013	Full payment received (date of receipt of payment) Request granted
	06.05.2013	Decision despatched
Fees paid	Renewal fee
	29.10.2012	Renewal fee patent year 03
	28.10.2013	Renewal fee patent year 04
	27.10.2014	Renewal fee patent year 05
	28.04.2016	Renewal fee patent year 06
	21.10.2016	Renewal fee patent year 07
	24.10.2017	Renewal fee patent year 08
	24.04.2019	Renewal fee patent year 09
	24.10.2019	Renewal fee patent year 10
	Penalty fee
	Additional fee for renewal fee
	31.10.2015	06 M06 Fee paid on 28.04.2016
	31.10.2018	09 M06 Fee paid on 24.04.2019
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	26.10.2010
	AL	11.12.2019
	AT	11.12.2019
	CY	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	MK	11.12.2019
	MT	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	TR	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
	[2022/32]
Former [2022/27]	HU	26.10.2010
	AL	11.12.2019
	AT	11.12.2019
	CY	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	MT	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	TR	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2022/26]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	TR	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2021/31]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/51]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/47]	AL	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/40]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/37]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	PT	06.05.2020
Former [2020/36]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	PT	06.05.2020
Former [2020/35]	AL	11.12.2019
	CZ	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/32]	AL	11.12.2019
	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/26]	ES	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/23]	ES	11.12.2019
	FI	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/22]	FI	11.12.2019
	LT	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
Former [2020/21]	NO	11.03.2020
Cited in	International search	[XI] WO2007109376 (NOVARTIS AG et al.)
		[XI] US2006204503 (FITCHETT JONATHON et al.)
		[A] GARCIA-RUDAZ CECILIA ET AL: "Fxna, a novel gene differentially expressed in the rat ovary at the time of folliculogenesis, is required for normal ovarian histogenesis.", DEVELOPMENT (CAMBRIDGE, ENGLAND) MAR 2007 LNKD- PUBMED:17267443, vol. 134, no. 5, March 2007 (2007-03-01), pages 945 - 957, XP002618324, ISSN: 0950-1991 DOI: http://dx.doi.org/10.1242/dev.02795
	by applicant	US2007237770
		US7105335
		US7285626
		US2008280779
		US43260406
		US2006035244
		US2003064439
		WO2005030250
		ADAMS G.P.; WEINER L.M.: "Monoclonal antibody therapy cancer", NAT BIOTECHNOL., vol. 23, 2005, pages 1147 - 57, XP002456710, DOI: doi:10.1038/nbt1137 DOI: http://dx.doi.org/10.1038/nbt1137
		KOHLER; MILSTEIN, NATURE, vol. 265, 1975, pages 495
		NUCLEIC ACIDS RES., vol. 18, no. 20, 25 October 1990 (1990-10-25), pages 6069 - 6074
		KONONEN J ET AL., NATURE MED., vol. 4, 1998, pages 844 - 847
		KALLIONIEMI OP ET AL., HUM. MOL. GENET., vol. 10, 2001, pages 657 - 662
		KAMPF C. ET AL., CLIN. PROTEOMICS, vol. 1, 2004, pages 285 - 300
		ANDERSON, L.; SEILHAMER, J.: "A comparison of selected mRNA and protein abundances in human liver", ELECTROPHORESIS, vol. 18, 1997, pages 533 - 537, XP008013305, DOI: doi:10.1002/elps.1150180333 DOI: http://dx.doi.org/10.1002/elps.1150180333
		CHEN, G.; GHARIB, T. G.; WANG, H.; HUANG, C. C.; KUICK, R.; THOMAS, D. G.; SHEDDEN, K. A.; MISEK, D. E.; TAYLOR, J. M.; GIORDANO,: "Protein profiles associated with survival in lung adenocarcinoma", PROC. NATL. ACAD. SCI. U. S. A, vol. 100, 2003, pages 13537 - 13542, XP055217585, DOI: doi:10.1073/pnas.2233850100 DOI: http://dx.doi.org/10.1073/pnas.2233850100
		GINESTIER, C.; CHARAFE-JAUFFRET, E.; BERTUCCI, F.; EISINGER, F.; GENEIX, J.; BECHLIAN, D.; CONTE, N.; ADELAIDE, J.; TOIRON, Y.; NG: "Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers", AM. J. PATHOL., vol. 161, 2002, pages 1223 - 1233, XP008013988
		GYGI, S. P.; ROCHON, Y.; FRANZA, B. R.; AEBERSOLD, R.: "Correlation between protein and mRNA abundance in yeast", MOL. CELL. BIOL., vol. 19, 1999, pages 1720 - 1730, XP002923559
		NISHIZUKA, S.; CHARBONEAU, L.; YOUNG, L.; MAJOR, S.; REINHOLD, W. C.; WALTHAM, M.; KOUROS-MEHR, H.; BUSSEY, K. J.; LEE, J. K.; ESP: "Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays", PROC. NATL. ACAD. SCI. U. S. A, vol. 100, 2003, pages 14229 - 14234, XP055291251, DOI: doi:10.1073/pnas.2331323100 DOI: http://dx.doi.org/10.1073/pnas.2331323100
		TYERS, M.; MANN, M.: "From genomics to proteomics", NATURE, vol. 422, 2003, pages 193 - 197
		KAGARA N; TANAKA N; NOGUCHI S; HIRANO T.: "Zinc and its transporter ZIP 10 are involved in invasive behavior of breast cancer cells", CANCER SCI., vol. 98, 2007, pages 692 - 697, XP002616766, DOI: doi:10.1111/j.1349-7006.2007.00446.x DOI: http://dx.doi.org/10.1111/j.1349-7006.2007.00446.x
		WILD P; SCHWIDETZKY U; CASTANOS-VELEZ E; LEHMANN K.: "Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients", INT J CANCER., vol. 117, 2005, pages 961 - 973, XP002457315, DOI: doi:10.1002/ijc.21235 DOI: http://dx.doi.org/10.1002/ijc.21235
		NGUYEN ST; HASEGAWA S; TSUDA H; TOMIOKA H; USHIJIMA M; NODA M; OMURA K; MIKI Y: "Identification of a predictive gene expression signature of cervical lymph node metastasis in oral squamous cell carcinoma.", CANCER SCI., vol. 98, 2007, pages 740 - 746
		GARCIA-RUDAZ,C.; LUNA,F.; TAPIA,V.; KERR,B.; COLGIN,L.; GALIMI,F.; DISSEN,G.A.; RAWLINGS,N.D.; OJEDA,S.R.: "Fxna, a novel gene differentially expressed in the rat ovary at the time of folliculogenesis, is required for normal ovarian histogenesis", DEVELOPMENT, vol. 134, 2007, pages 945 - 957, XP002618324, DOI: doi:10.1242/dev.02795 DOI: http://dx.doi.org/10.1242/dev.02795
		KRATZSCHMAR J; HAENDLER B; EBERSPAECHER U; ROOSTERMAN D; DONNER P; SCHLEUNING WD: "The human cysteine-rich secretory protein (CRISP) family. Primary structure and tissue distribution of CRISP-1, CRISP-2 and CRISP-3", EUR J BIOCHEM., vol. 236, 1996, pages 827 - 836, XP000997999, DOI: doi:10.1111/j.1432-1033.1996.t01-1-00827.x DOI: http://dx.doi.org/10.1111/j.1432-1033.1996.t01-1-00827.x
		BJARTELL,A.; JOHANSSON,R.; BJORK,T.; ADALEANU,V.; LUNDWALL,A.; LILJA,H.; KJELDSEN,L.; UDBY,L.: "Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland", PROSTATE, vol. 66, 2006, pages 591 - 603
		BJARTELL,A.S.; AL-AHMADIE,H.; SERIO,A.M.; EASTHAM,J.A.; EGGENER,S.E.; FINE,S.W.; UDBY,L.; GERALD,W.L.; VICKERS,A.J.; LILJA,H.: "Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy", CLIN. CANCER RES., vol. 13, 2007, pages 4130 - 4138

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.3.42; 39p